Skip to main content

Table 1 Baseline characteristics of the study cohort

From: Closed-loop oxygen control improves oxygen therapy in acute hypoxemic respiratory failure patients under high flow nasal oxygen: a randomized cross-over study (the HILOOP study)

Variables

Median (IQR) or mean (SD) or n (%)

Age

49 (40 to 62)

Sex (male)

24 (53.3%)

Comorbidities

 Hypertension

11 (24.0%)

 Diabetes

7 (15.5%)

 Immunosupressiona

10 (22.2%)

 Chronic respiratory diseaseb

6 (13.3%)

Reason for admission

 COVID-19 pneumonia

36 (80.0%)

 Non-COVID pneumonia

5 (11.1%)

 Other

4 (8.8%)

Type of acute respiratory failure

 De novo AHRF

41 (92.2%)

 Postextubation support

4 (8.8%)

HFNO characteristics at inclusion

 Hours of HFNO therapy

24 (10 to 48)

 FIO2

0.50 (0.45 to 0.60)

 Flow (L/min)

50 (40 to 50)

Severity scores

 SAPS3

45 (39 to 52)

 APACHE II

8.5 (5.0 to 15.3)

 SOFA

3 (3 to 3)

Outcomes

 ICU length of stay (days)

8 (5 to 15)

 Need for mechanical ventilation

12 (26%)

 Days of mechanical ventilation

9 (8 to 14)

 ICU mortality

2 (4.4%)

 Hospital length of stay (days)

16 (9 to 30)

 Hospital mortality

4 (4.4%)

  1. IQR: interquartile range; SD: standard deviation; COVID-19: coronavirus-2 disease; AHRF: acute hypoxemic respiratory failure; HFNO: high flow nasal oxygen; SAPS3: Simplified Acute Physiology Score III; APACHE II: Acute Physiology And Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; ICU: Intensive Care Unit
  2. aIncludes patients with solid or hematologic neoplasms, organ transplant or inflammatory disease receiving immunosuppressing treatment
  3. bIncludes chronic obstructive pulmonary disease (COPD), asthma, interstitial disease and obstructive sleep apnea syndrome (OSAS)